Dissemination of evidence-based antipsychotic prescribing guidelines to nursing homes: A cluster randomized trial

Journal of the American Geriatrics Society

Volumn 63, Issue 7, 2015, Pages 1289-1298

  Tjia, Jennifer ^a,b   Field, Terry ^a,b   Mazor, Kathleen ^a,b   Lemay, Celeste A ^a,b   Kanaan, Abir O ^a,c   Donovan, Jennifer L ^a,c   Briesacher, Becky A ^a,b   Peterson, Daniel ^a,b   Pandolfi, Michelle ^d   Spenard, Ann ^d   Gurwitz, Jerry H ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d QUALIDIGM   (United States)

Author keywords

antipsychotics; clinical trial; inappropriate drug use; nursing homes; quality of care

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PRESCRIPTION DRUG; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; GERONTOPSYCHIATRY; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; INFORMATION DISSEMINATION; LEADERSHIP; MEDICAL AUDIT; MEDICAL EDUCATION; NURSING HOME; NURSING HOME PATIENT; NURSING HOME PERSONNEL; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TOTAL QUALITY MANAGEMENT; UNITED STATES; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; CONNECTICUT; EVIDENCE-BASED MEDICINE; HUMANS; INFORMATION DISSEMINATION; NURSING HOMES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 84937467759     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13488     Document Type: Article

References (37)

1. Chen Y, Briesacher BA, Field TS, et al., Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010; 170: 89-95.
2. Department of Health and Human Services, Office of the Inspector General. Medicare atypical antipsychotic drug claims for elderly nursing home residents, 2011 [on-line]. Available at http://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf Accessed February 19, 2014.
3. Ballard C, Day S, Sharp S, et al., Neuropsychiatric symptoms in dementia: Importance and treatment considerations. Int Rev Psychiatry 2008; 20: 396-404.
4. Gill SS, Bronskill SE, Normand S-LT, et al., Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775-786.
5. Jeste DV, Blazer D, Casey D, et al., ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33: 957-970.
6. Madhusoodanan S, Shah P, Brenner R, et al., Pharmacological treatment of the psychosis of Alzheimer's disease: What is the best approach? CNS Drugs 2007; 21: 101-115.
7. Ray WA, Chung CP, Murray KT, et al., Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-235.
8. Wang PS, Schneeweiss S, Avorn J, et al., Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335-2341.
9. U.S. Department of Health and Human Services, Food and Drug Administration, Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances, 2005 [on-line]. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm Accessed April 23, 2015.
10. U.S. Department of Health and Human Services, Food and Drug Administration, Information for Healthcare Professionals: Conventional Antipsychotics, 2008 [on-line]. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm Accessed April 23, 2015.
11. Maher AR, Maglione M, Bagley S, et al., Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA 2011; 306: 1359-1369.
12. Maglione M, Maher AR, Hu J-H, et al., Off-Label Use of Atypical Antipsychotics: An Update. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
13. Kuehn BM,. Efforts stall to curb nursing home antipsychotic use. JAMA 2013; 310: 1109-1110.
14. Balas EA, Boren SA,. Managing clinical knowledge for health care improvement. In:, Bemmel J, McCray AT, eds. Yearbook of Medical Informatics 2000: Patient-Centered Systems. Stuttgart, Germany: Schattauer, 2000, pp 65-70.
15. Green LW, Ottoson JM, Garcia C, et al., Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annu Rev Public Health 2009; 30: 151-174.
16. Yuan CT, Nembhard IM, Stern AF, et al., Blueprint for the dissemination of evidence-based practices in health care. Issue Brief. The Commonwealth Fund. May 2010.
17. Jamtvedt G, Young JM, Kristoffersen DT, et al., Audit and feedback: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2003;(3): CD000259.
18. Soumerai SB, Avorn J,. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA 1990; 263: 549-556.
19. Hughes CM, Lapane K, Watson MC, et al., Does organisational culture influence prescribing in care homes for older people? A new direction for research. Drugs Aging 2007; 24: 81-93.
20. Tjia J, Gurwitz JH, Briesacher BA,. The challenge of changing nursing home prescribing culture. Am J Geriatr Pharmacother 2012; 10: 37-46.
21. Glasgow RE, Klesges LM, Dzewaltowski DA, et al., Evaluating the impact of health promotion programs: Using the RE-AIM framework to form summary measures for decision making involving complex issues. Health Educ Res 2006; 21: 688-694.
22. Effective Health Care. Off-Label use of atypical antipsychotics: a summary for clinician and policymakers [online]. Available at http://www.effectivehealthcare.ahrq.gov/repFiles/Atypical-Antipsychotics-Off-Label-Use.pdf Accessed January 6, 2014.
23. Lemay CA, Mazor KM, Field TS, et al., Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff. J Am Med Dir Assoc 2013; 14: 895-900.
24. Avorn J, Soumerai SB, Everitt DE, et al., A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 1992; 327: 168-173.
25. Nursing home compare [on-line]. Available at http://www.medicare.gov/nursinghomecompare/search.html Accessed January 6, 2014.
26. Shadish WR, Cook TD, Campbell DT,. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin Co., 2002.
27. Durbin J, Watson GS,. Testing for serial correlation in least squares regression II. Biometrika 1951; 38: 159-179.
28. Centers for Medicare and Medicaid Services. Improving dementia care and reducing unnecessary use of antipsychotic medications in nursing homes. National provider call, Medicare learning network [on-line]. Available at http://media.wix.com/ugd/45f182-2c1ef9dd577a4131b6cd4235f30949e7.pdf Accessed January 6, 2014.
29. Centers for Medicare and Medicaid Services. New data show antipsychotic drug use is down in nursing homes nationwide [on-line]. Available at http://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-Releases/2013-Press-Releases-Items/2013-08-27.html Accessed January 6, 2014.
30. Department of Health and Human Services, Office of Inspector General. Report OEI 07-08-00150. Medicare atypical antipsychotic drug claims for elderly nursing home residents. May 2011 [on-line]. Available at http://oig.hhs.gov/+oei/reports/oei-07-08-00150.pdf Accessed January 6, 2014.
31. Health Care Financing Administration: Medicare and Medicaid: requirements for long-term care facilities, final regulations. Federal Register 56:48865-48921, September 26, 1991.
32. Tjia J, Field T, Lemay C, et al., Antipsychotic use in nursing homes varies by psychiatric consultant. Med Care 2014; 52: 267-271.
33. CMS manual system. Pub 100-07 State Operations Provider Certification. Transmittal 22. Tag F329 (Rev 22; Issued 12-15-06; Effective/Implementation: 12-18-06) 483.25(l). Unnecessary Drugs [on-line]. Available at http://www.cms.hhs.gov/transmittals/downloads/R22SOMA.pdf Accessed October 30, 2014.
34. Levenson SA, Saffel DA,. The consultant pharmacist and the physician in the nursing home: Roles, relationships, and a recipe for success. J Am Med Dir Assoc 2007; 8: 55-64.
35. Ivers N, Jamtvedt G, Flottorp S, et al., Audit and feedback: Effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012;(6): CD000259.
36. Colon-Emeric CS, Lyles KW, House P, et al., Randomized trial to improve fracture prevention in nursing home residents. Am J Med 2007; 120: 886-892.
37. Rahman AN, Applebaum RA, Schnelle JF, et al., Translating research into practice in nursing homes: Can we close the gap? Gerontologist 2012; 52: 597-606.